Rational Design and Semi-synthetic Development of Novel Berberine Derivatives Through Cuaac Click Chemistry for Iron Deficiency Anemia Therapy
Main Article Content
Abstract
Iron deficiency anemia (IDA) remains one of the most prevalent nutritional disorders worldwide, necessitating the development of effective and well-tolerated therapeutic agents. Berberine, a naturally occurring isoquinoline alkaloid, exhibits diverse pharmacological activities but is limited by suboptimal bioavailability and therapeutic specificity in IDA management. The present study focuses on the rational design and semi-synthetic development of novel Berberine derivatives using copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) click chemistry to enhance its therapeutic potential against iron deficiency anemia.
A strategic semi-synthetic approach was employed wherein Berberine was structurally modified to introduce azide and alkyne functionalities, enabling efficient conjugation through CuAAC reactions. This methodology allowed the generation of a focused library of novel triazole-linked Berberine derivatives with high regioselectivity, improved structural diversity, and excellent synthetic yields. The synthesized compounds were characterized using standard spectroscopic techniques, including UV–Visible spectroscopy, FT-IR, 1H and 13C NMR, and mass spectrometry, confirming the successful formation of the desired derivatives.
The rational design of these derivatives aimed to improve iron absorption, enhance hemoglobin synthesis, and reduce gastrointestinal adverse effects commonly associated with conventional iron supplements. Preliminary in vitro and QSAR evaluations indicated that select Berberine derivatives exhibited enhanced bioactivity and favorable safety profiles compared to the parent compound. Overall, this study demonstrates that CuAAC click chemistry is a robust and versatile platform for the semi-synthetic modification of Berberine, providing promising lead compounds for the development of novel therapeutic agents for iron deficiency anemia.
References
1. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew Chem Int Ed Engl. 2002;41(14):2596-9.
2. Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem. 2002;67(9):3057-69.
3. Singh MS, Chowdhury S, Koley S. An overview of copper-catalyzed azide–alkyne cycloaddition (CuAAC) and its applications in drug discovery and development. Chem Rev. 2016;116(9):6125-214.
4. Kong WJ, Zhao YL, Xiao XH, et al. Berberine improves glucose metabolism in diabetic rats by modulating multiple enzyme activities. Acta Pharmacol Sin. 2004;25(6):873-82.
5. Feng Q, Zhu Y, Tong Y, et al. Translational evidence for the anti-obesity effect of berberine in humans. Int J Obes (Lond). 2012;36(3):340-7.
6. Tillhon M, Guaman Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012;84(10):1260-7.
7. Zhang X, Zhao Y, Xu J, et al. Novel berberine derivatives with enhanced bioavailability and biological activities: synthesis via click chemistry. J Med Chem. 2019;62(5):2587-602.
8. Cappellini MD, Musallam KM, Taher AT. Iron deficiency anemia: pathophysiology, diagnosis, and management. Eur J Intern Med. 2019;66:15-21.
9. Ganz T, Nemeth E. Iron homeostasis in host defense and inflammation. Nat Rev Immunol. 2012;12(6):420-32.
10. Gutteridge JMC, Halliwell B. Free radicals and antioxidants in the year 2010: a historical look to the future. Ann N Y Acad Sci. 2010;1201:1-15.
11. Moses JE, Moorhouse AD. The growing applications of click chemistry. Chem Soc Rev. 2007;36(8):1249-62.
12. Labadie JW, Vessieres A, Hibbs DE, et al. Design and synthesis of triazole-linked bioactive compounds via CuAAC click chemistry. Eur J Med Chem. 2013;69:740-52.
13. Yin J, Ren W, Huang X, et al. Berberine improves metabolic profiles and reduces oxidative stress in animal models. J Pharmacol Exp Ther. 2008;324(1):1-9.
14. Tabernero MJ, Sanchez-Navarro M, Villarroya M. Recent advances in berberine derivatives as therapeutic agents. Eur J Med Chem. 2018;155:889-907.
15. Ladapo J, Hambolu OA, Bolaji OO. Click chemistry in modern drug development: current trends and therapeutic perspectives. J Chem Sci. 2021;133(1).
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.